Yoshitaka Okamoto Selected Research

Squamous Cell Carcinoma (Epidermoid Carcinoma)

12/2018	Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer.
4/2016	Carbon ion radiotherapy for locally advanced squamous cell carcinoma of the external auditory canal and middle ear.
4/2013	MicroRNAs function as tumor suppressors or oncogenes: aberrant expression of microRNAs in head and neck squamous cell carcinoma.
9/2012	The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways.
1/2012	Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma.
11/2011	Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma.
8/2011	Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC).
7/2011	Craniofacial Resection for Sinonasal Malignant Tumors: Statistical Analysis of Surgical Outcome over 17 Years at a Single Institution.
2/2009	The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma.
11/2005	Preoperative chemotherapy and radiation therapy for squamous cell carcinoma of the maxillary sinus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshitaka Okamoto Research Topics

Disease

43	Neoplasms (Cancer) 12/2019 - 03/2005
29	Squamous Cell Carcinoma of Head and Neck 04/2021 - 12/2007
24	Allergic Rhinitis 10/2022 - 01/2009
21	Seasonal Allergic Rhinitis (Hay Fever) 03/2022 - 01/2008
16	Hypersensitivity (Allergy) 10/2022 - 06/2004
13	Asthma (Bronchial Asthma) 12/2021 - 06/2010
12	Inflammation (Inflammations) 11/2018 - 03/2005
10	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2018 - 11/2005
9	Head and Neck Neoplasms (Head and Neck Cancer) 04/2016 - 11/2007
7	Carcinogenesis 04/2021 - 01/2009
5	Infections 01/2021 - 10/2006
5	Carcinoma (Carcinomatosis) 01/2017 - 05/2003
4	Anaphylaxis (Anaphylactic Shock) 01/2022 - 02/2014
4	Rhinosinusitis 11/2021 - 02/2015
4	Rhinitis 11/2019 - 01/2012
4	Neoplasm Metastasis (Metastasis) 02/2016 - 10/2008
3	COVID-19 01/2021 - 10/2020
3	Melanoma (Melanoma, Malignant) 07/2017 - 05/2009
3	Respiratory Tract Infections (Respiratory Tract Infection) 08/2007 - 04/2006
2	Gastroesophageal Reflux (GERD) 01/2022 - 01/2020
2	Nasal Polyps (Nasal Polyp) 11/2021 - 02/2015
2	Perennial Allergic Rhinitis 01/2021 - 02/2005
2	Pyogenic Granuloma 01/2017 - 04/2016
2	Adenoid Cystic Carcinoma (Cylindroma) 01/2016 - 04/2012
2	Immunoglobulin G4-Related Disease 01/2012 - 01/2010
2	Food Hypersensitivity (Food Allergy) 01/2012 - 01/2012
2	Esophageal Squamous Cell Carcinoma 08/2011 - 01/2011
1	Exercise-Induced Allergies 01/2022
1	Respiratory Tract Diseases (Respiratory Tract Disease) 12/2021
1	Hemorrhagic Stroke 08/2021
1	Virus Diseases (Viral Diseases) 04/2021
1	Airway Obstruction (Choking) 01/2021
1	Eczema 01/2021
1	Dermatitis 01/2021
1	Crohn Disease (Crohn's Disease) 01/2021
1	Biotin deficiency 01/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2020
1	Esophagitis 01/2020

Drug/Important Bio-Agent (IBA)

19	MicroRNAs (MicroRNA)IBA 08/2018 - 01/2011
13	AllergensIBA 12/2021 - 06/2009
9	Immunoglobulin E (IgE)IBA 01/2020 - 02/2005
8	Proteins (Proteins, Gene)FDA Link 10/2018 - 01/2011
8	Messenger RNA (mRNA)IBA 01/2018 - 12/2007
7	TabletsIBA 03/2022 - 11/2016
5	AntigensIBA 12/2018 - 01/2010
5	RNA (Ribonucleic Acid)IBA 08/2018 - 05/2017
5	Biomarkers (Surrogate Marker)IBA 03/2012 - 02/2009
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 04/2016
3	Pharmaceutical PreparationsIBA 10/2022 - 01/2015
3	alpha-galactosylceramideIBA 07/2019 - 03/2008
3	Histamine Antagonists (Antihistamines)IBA 01/2019 - 09/2012
3	IntegrinsIBA 01/2018 - 05/2017
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2017 - 11/2013
3	LigandsIBA 09/2016 - 01/2009
3	CarbonIBA 04/2014 - 05/2009
2	Proton Pump InhibitorsIBA 01/2022 - 01/2020
2	Epinephrine (Adrenaline)FDA LinkGeneric 01/2022 - 01/2019
2	Monoclonal AntibodiesIBA 11/2021 - 11/2018
2	DNA (Deoxyribonucleic Acid)IBA 04/2021 - 12/2007
2	EnzymesIBA 01/2021 - 03/2012
2	Immunoglobulin G (IgG)IBA 01/2020 - 01/2008
2	Liposomes (Liposome)IBA 07/2019 - 03/2010
2	AntibodiesIBA 12/2018 - 05/2008
2	LuciferasesIBA 08/2018 - 02/2016
2	ErbB Receptors (EGF Receptor)IBA 01/2018 - 01/2017
2	Small Interfering RNA (siRNA)IBA 01/2018 - 03/2012
2	Therapeutic UsesIBA 01/2018 - 10/2011
2	Interleukin-13IBA 01/2017 - 06/2010
2	Interleukin-5 (Interleukin 5)IBA 01/2017 - 02/2015
2	CytokinesIBA 06/2016 - 01/2010
2	VaccinesIBA 02/2015 - 03/2010
2	Galactosylceramides (Galactocerebrosides)IBA 03/2011 - 02/2011
2	Anti-Infective Agents (Microbicides)IBA 08/2007 - 10/2006
2	Penicillins (Penicillin)FDA Link 10/2006 - 04/2006
1	azelastine (Optivar)FDA LinkGeneric 10/2022
1	Fluticasone (Cutivate)FDA LinkGeneric 10/2022
1	sho-seiryu-toIBA 03/2022
1	benralizumabIBA 11/2021
1	COVID-19 VaccinesIBA 10/2021
1	1- cyclohexyl- 3- (2- (4- morpholinyl)ethyl)carbodiimideIBA 08/2021
1	Biological ProductsIBA 04/2021
1	Biotin (Vitamin H)FDA Link 01/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	AnkyrinsIBA 01/2021
1	Pepsin A (Pepsin)IBA 01/2020

Therapy/Procedure

16	Immunotherapy 01/2022 - 05/2008
10	Radiotherapy 12/2018 - 05/2003
8	Drug Therapy (Chemotherapy) 10/2022 - 11/2005
8	Therapeutics 01/2022 - 06/2009
8	Heavy Ion Radiotherapy 07/2017 - 05/2009
4	Injections 10/2021 - 10/2006
3	Complementary Therapies (Alternative Medicine) 07/2017 - 10/2011
3	Intra-Arterial Infusions 03/2011 - 06/2009
2	Sublingual Administration 07/2019 - 01/2015
1	Transcranial Magnetic Stimulation 08/2021
1	Precision Medicine 01/2021
1	Tonsillectomy 01/2021
1	Duration of Therapy 10/2020
1	Chemoradiotherapy 04/2020